FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025657113> ?p ?o ?g. }

• W3025657113 endingPage "1336" @default.
• W3025657113 startingPage "1325" @default.
• W3025657113 abstract "The purpose of this study was to determine phenotypes characterizing cardiac involvement in AL amyloidosis by using direct (fluorine-18-labeled florbetapir {[18F]florbetapir} positron emission tomography [PET]/computed tomography) and indirect (echocardiography and cardiac magnetic resonance [CMR]) imaging biomarkers of AL amyloidosis. Cardiac involvement in systemic light chain amyloidosis (AL) is the main determinant of prognosis and, therefore, guides management. The hypothesis of this study was that myocardial AL deposits and expansion of extracellular volume (ECV) could be identified before increases in N-terminal pro–B-type natriuretic peptide or wall thickness. A total of 45 subjects were prospectively enrolled in 3 groups: 25 with active AL amyloidosis with cardiac involvement (active-CA), 10 with active AL amyloidosis without cardiac involvement by conventional criteria (active-non-CA), and 10 with AL amyloidosis with cardiac involvement in remission for at least 1 year (remission-CA). All subjects underwent echocardiography, CMR, and [18F]florbetapir PET/CT to evaluate cardiac amyloid burden. The active-CA group demonstrated the largest myocardial AL amyloid burden, quantified by [18F]florbetapir retention index (RI) 0.110 (interquartile range [IQR]: 0.078 to 0.139) min−1, and the lowest cardiac function by global longitudinal strain (GLS), median GLS −11% (IQR: −8% to −13%). The remission-CA group had expanded extracellular volume (ECV) and [18F]florbetapir RI of 0.097 (IQR: 0.070 to 0.124 min−1), and abnormal GLS despite hematologic remission for >1 year. The active-non-CA cohort had evidence of cardiac amyloid deposition by advanced imaging metrics in 50% of the subjects; cardiac involvement was identified by late gadolinium enhancement in 20%, elevated ECV in 20%, and elevated [18F]florbetapir RI in 50%. Evidence of cardiac amyloid infiltration was found based on direct and indirect imaging biomarkers in subjects without CA by conventional criteria. The findings from [18F]florbetapir PET imaging provided insight into the preclinical disease process and on the basis of interpretation of expanded ECV on CMR and have important implications for future research and clinical management of AL amyloidosis. (Molecular Imaging of Primary Amyloid Cardiomyopathy [MICA]; NCT02641145)" @default.
• W3025657113 created "2020-05-21" @default.
• W3025657113 creator A5000578249 @default.
• W3025657113 creator A5001396698 @default.
• W3025657113 creator A5003055083 @default.
• W3025657113 creator A5005111256 @default.
• W3025657113 creator A5010198450 @default.
• W3025657113 creator A5044226573 @default.
• W3025657113 creator A5045641510 @default.
• W3025657113 creator A5052626419 @default.
• W3025657113 creator A5055089118 @default.
• W3025657113 creator A5056428329 @default.
• W3025657113 creator A5069060124 @default.
• W3025657113 creator A5071439155 @default.
• W3025657113 creator A5079528320 @default.
• W3025657113 creator A5084430398 @default.
• W3025657113 creator A5084831561 @default.
• W3025657113 creator A5086225362 @default.
• W3025657113 creator A5086342448 @default.
• W3025657113 date "2020-06-01" @default.
• W3025657113 modified "2023-10-18" @default.
• W3025657113 title "Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis" @default.
• W3025657113 cites W1523022925 @default.
• W3025657113 cites W1991532291 @default.
• W3025657113 cites W2076467505 @default.
• W3025657113 cites W2084522929 @default.
• W3025657113 cites W2088110121 @default.
• W3025657113 cites W2098093182 @default.
• W3025657113 cites W2101817311 @default.
• W3025657113 cites W2113549638 @default.
• W3025657113 cites W2118848299 @default.
• W3025657113 cites W2132750428 @default.
• W3025657113 cites W2153784828 @default.
• W3025657113 cites W2443994174 @default.
• W3025657113 cites W2522056109 @default.
• W3025657113 cites W2548150178 @default.
• W3025657113 cites W2554655675 @default.
• W3025657113 cites W2606253069 @default.
• W3025657113 cites W2795216925 @default.
• W3025657113 cites W2797258586 @default.
• W3025657113 cites W2887075678 @default.
• W3025657113 cites W4249896096 @default.
• W3025657113 doi "https://doi.org/10.1016/j.jcmg.2020.02.025" @default.
• W3025657113 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8218539" @default.
• W3025657113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32417333" @default.
• W3025657113 hasPublicationYear "2020" @default.
• W3025657113 type Work @default.
• W3025657113 sameAs 3025657113 @default.
• W3025657113 citedByCount "38" @default.
• W3025657113 countsByYear W30256571132020 @default.
• W3025657113 countsByYear W30256571132021 @default.
• W3025657113 countsByYear W30256571132022 @default.
• W3025657113 countsByYear W30256571132023 @default.
• W3025657113 crossrefType "journal-article" @default.
• W3025657113 hasAuthorship W3025657113A5000578249 @default.
• W3025657113 hasAuthorship W3025657113A5001396698 @default.
• W3025657113 hasAuthorship W3025657113A5003055083 @default.
• W3025657113 hasAuthorship W3025657113A5005111256 @default.
• W3025657113 hasAuthorship W3025657113A5010198450 @default.
• W3025657113 hasAuthorship W3025657113A5044226573 @default.
• W3025657113 hasAuthorship W3025657113A5045641510 @default.
• W3025657113 hasAuthorship W3025657113A5052626419 @default.
• W3025657113 hasAuthorship W3025657113A5055089118 @default.
• W3025657113 hasAuthorship W3025657113A5056428329 @default.
• W3025657113 hasAuthorship W3025657113A5069060124 @default.
• W3025657113 hasAuthorship W3025657113A5071439155 @default.
• W3025657113 hasAuthorship W3025657113A5079528320 @default.
• W3025657113 hasAuthorship W3025657113A5084430398 @default.
• W3025657113 hasAuthorship W3025657113A5084831561 @default.
• W3025657113 hasAuthorship W3025657113A5086225362 @default.
• W3025657113 hasAuthorship W3025657113A5086342448 @default.
• W3025657113 hasBestOaLocation W30256571132 @default.
• W3025657113 hasConcept C119060515 @default.
• W3025657113 hasConcept C126322002 @default.
• W3025657113 hasConcept C126838900 @default.
• W3025657113 hasConcept C142724271 @default.
• W3025657113 hasConcept C143409427 @default.
• W3025657113 hasConcept C159654299 @default.
• W3025657113 hasConcept C164705383 @default.
• W3025657113 hasConcept C185592680 @default.
• W3025657113 hasConcept C203014093 @default.
• W3025657113 hasConcept C2113261 @default.
• W3025657113 hasConcept C2775842073 @default.
• W3025657113 hasConcept C2776008845 @default.
• W3025657113 hasConcept C2777607188 @default.
• W3025657113 hasConcept C2777633098 @default.
• W3025657113 hasConcept C2779551797 @default.
• W3025657113 hasConcept C2779951007 @default.
• W3025657113 hasConcept C28406088 @default.
• W3025657113 hasConcept C2989005 @default.
• W3025657113 hasConcept C36394416 @default.
• W3025657113 hasConcept C55493867 @default.
• W3025657113 hasConcept C71924100 @default.
• W3025657113 hasConceptScore W3025657113C119060515 @default.
• W3025657113 hasConceptScore W3025657113C126322002 @default.
• W3025657113 hasConceptScore W3025657113C126838900 @default.
• W3025657113 hasConceptScore W3025657113C142724271 @default.
• W3025657113 hasConceptScore W3025657113C143409427 @default.

• next